SB-728-T

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameSB-728-T

Drug Alias NameZFP TherapeuticSB-728mR-TSB-728-T

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Gene editing > Zinc Finger Nucleases technologyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionC-C chemokine receptor type 5 modulators

TargetsC-C chemokine receptor type 5

Therapy Area/IndicationsHIV Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesPuerto Rico

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesSangamo Biosciences

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Cincinnati

Inactive CompaniesSangamo Therapeutics Inc University Of Pennsylvania

Active IndicationsHIV Infections

Inactive IndicationsN/A

Other Information

ATC CodeN/A